Drug intelligence / Profile preview

carboplatin + docetaxel + nab-paclitaxel + pertuzumab + trastuzumab

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination therapy used in the treatment of HER2-positive breast cancer. The regimen combines several anti-cancer agents with different mechanisms of action: 1. Carboplatin: A platinum-based chemotherapy agent 2. Docetaxel: A taxane chemotherapy agent 3. Nab-paclitaxel: An albumin-bound formulation of paclitaxel (another taxane) 4. Pertuzumab: A monoclonal antibody targeting HER2 dimerization domain II 5. Trastuzumab: A monoclonal antibody targeting a different epitope of HER2 The combination provides dual HER2 blockade (pertuzumab and trastuzumab) along with cytotoxic chemotherapy agents. Clinical trials have shown that this combination can be effective in treating HER2-positive breast cancer, particularly in neoadjuvant settings.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on carboplatin + docetaxel + nab-paclitaxel + pertuzumab + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + docetaxel + nab-paclitaxel + pertuzumab + trastuzumab.

Explore the full profile